NASDAQ:HALO

Halozyme Therapeutics Stock News

etoro logo Buy HALO
*Your capital is at risk
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Technically speaking, the major U.S. benchmarks are poised to conclude June against an increasingly uneven, but still generally bullish, bigger-picture...
Piper Sandler restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report released on Monday, TipRanks reports. The firm currently has a $28.00 price target on the
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) ADC Therapeutics SA (...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection,
Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the recipient of some unusual options trading on Tuesday. Stock traders bought 3,334 call options on the company. This is an increase of approximately 280
Wells Fargo & Company MN increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.9% during the first quarter, according to the company in its most recent disclosure with th
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $10 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License A
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Deutsche Bank AG cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 22.7% during the first quarter, according to the company in its most recent 13F filing with the Securities a
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the upcoming BMO 2020 Prescriptions for Success Health
In this article you are going to find out whether hedge funds think Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a good investment right now. We like to check what the smart money thinks first before
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE